Allogene Therapeutics Inc. will lease 118,000 square feet in Newark for a facility to make off-the-shelf, ready-to-use cell therapies for a range of diseases.
The South San Francisco-based company (NASDAQ: ALLO) said Wednesday that it leased a full building in Gateway 84, a three-building, 23-acre complex under development by a joint venture of Panattoni Development Co. and Clarion Partners at 7300 Gateway Blvd. It initially will pay $16.20 a square foot for the lease, increasing 3 percent annually over the term of 15 years and eight months.
For the full story, go to San Francisco Business Times.
© 2019 American City Business Journals. All rights reserved.
